REducing future fractureS and improving ouTcOmes of fRagility fracturE

The purpose of the Fracture Prevention Program is to evaluate methods for

caring for patients after a recent bone break or fracture. Participants with a recent bone break, who have a regular doctor, and who do not have certain medical
conditions (cancer, severe kidney disease, or other bone diseases) and who don’t take certain medications will be asked to be part of the research study.

This is Fracture Prevention Program for up to 24 months (2 years).
Participants will be contacted via telephone to complete a baseline survey. After
completing the baseline survey, you will be contacted 12 and 24 months later to
complete another survey. Each survey will take 15-20 minutes to complete.

Inclusion:

• Age 50 years and older (no upper age limit)

• Sustained a primary fragility fracture (hip/femur, pelvis, clinical spine, humerus, wrist) in the last 12 months
o Hip/femur includes femoral head, trochanter, femoral neck, proximal femur (excludes distal femur, middle femur, femoral shaft, supracondylar fracture, “closer to the knee”)
o Pelvis includes ischium, ilium, acetabulum, sacrum (excludes coccyx, tailbone)
o Clinical spine includes thoracic or lumbar vertebrae compression fractures or burst fractures (excludes cervical spine, coccyx)
o Humerus includes proximal humerus, upper arm (excludes distal humerus, middle humerus, humeral shaft, collar bone, elbow)
o Wrist includes distal radius, distal ulna, radial styloid, ulnar styloid, colles fracture (excludes proximal ulna, proximal radius, scaphoid, hand, carpals, boxer fracture, elbow)
• Participant must self-identify a regular primary care provider (PCP)
• Participant must provide a mailing address

Exclusion:

• Exposure to the following medications in the prior 12 months;
-Actonel or Atelvia (risedronate)
-Fosamax or Binosto (alendronate)

- Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate)
- Boniva or Bondronat (ibandronate)
- Aredia (pamidronate)
- Prolia (denosumab)
- Evenity (romozosumab)
- Tymlos (abaloparatide)
- Forteo (teriparatide)
- Natpara (parathyroid hormone)
- Evista (raloxifene)
- Conbriza or Viviant (bazedoxifene)
- Duavee (bazedoxifene-conjugated estrogen)
- Miacalcin (calcitonin)

• Diagnosis of the following medical conditions;
- CKD stage 4 or 5 or on dialysis
- Multiple myeloma
- Addison’s disease
- Adrenal insufficiency
- Enrolled hospice care
- Solid organ transplant, or expecting a solid organ transplant
- Bone marrow transplant
• History of metabolic bone disease (except osteoporosis) such as Paget’s disease, osteomalacia, osteogenesis imperfecta, or Cushing’s disease
• Fractures resulting from severe trauma (e.g. motor vehicle accidents, a fall from 2 feet or higher elevation)
• Pathologic fractures secondary to malignancy or infection
• Scheduled appointment with a bone health specialist
• Participant unable to consent on their own (cognitive impairment, dementia, etc.)
• Currently enrolled in another research study that requires taking medication